Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 193–216 of 328
Akkermansia and Postbiotics Target Metabolic Health Beyond Digestion
Designs for Health has launched Akkermansia Pro GLP-1 Probiotic, combining live Akkermansia muciniphila with a clinically studied postbiotic (BPL1) to support metabolic health, blood sugar control, and body composition. This product represents a shift in the microbiome industry away from generic digestive probiotics toward targeted metabolic interventions informed by emerging research on gut-metabolism signaling.
Senescent Cell Removal Plus Stem Cell Restoration Extends Lifespan 70%
Immorta Bio's AI-driven dual-target approach simultaneously addresses senescent cell accumulation and stem cell decline, demonstrating 70% mean and 80% median lifespan extension in preclinical models. The platform integrates personalized medicine with senolytic immunotherapy and cellular rejuvenation, suggesting a mechanistic approach to systemic longevity rather than single-pathway intervention.
Niagen launches telehealth NAD+ injection platform
Niagen Bioscience launched a prescription-only telehealth platform delivering subcutaneous NAD+ injections at home, shifting nicotinamide riboside from over-the-counter supplement to clinician-directed pharmaceutical intervention. The model combines telehealth access with clinical oversight and compounded pharmaceutical-grade dosing, though the clinical evidence supporting NAD+ supplementation for meaningful longevity outcomes remains incomplete.
Nuchido announced as Catalyst Partner for The Longevity Show
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
Antioxidants selectively clear senescent muscle cells
Antioxidants can selectively eliminate senescent cells in muscle tissue by modulating mTOR signaling, restoring proper nutrient sensing that these aged cells have lost. This mechanism offers a targeted approach to removing dysfunctional cells without broad-spectrum intervention, with direct implications for maintaining muscle integrity and metabolic function in aging.
Senescent Cells Block Cellular Cleanup in Aging
Cellular senescence and autophagy dysfunction accumulate with age, driving multiple organ system decline. Understanding how senescent cells disrupt normal repair mechanisms reveals intervention points for extending healthspan independent of chronological age.
Senotype classification reframes cellular aging as adaptive or pathological
Senescent cells—those that have stopped dividing—exhibit distinct molecular profiles and functional outcomes depending on their origin and microenvironment. This classification framework clarifies why some senescent states support tissue repair while others drive chronic inflammation and age-related disease, fundamentally shifting how we interpret cellular aging.
Niagen Bioscience launches Niagen Plus telehealth platform
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
Antioxidants eliminate senescent muscle cells via redox targeting
Senescent muscle precursor cells depend on ROS-driven Akt/mTORC1 signaling to maintain their dysfunctional state. Antioxidant treatment can suppress this pathway, reduce inflammatory output, and selectively eliminate senescent cells while sparing healthy muscle precursors—a mechanism relevant to cellular senescence reversal strategies in aging muscle.
Clearance of Senescent Cells by BCLXL‐PROTAC: A Novel Approach to Treat COPD?
BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.
Cell cycle inhibitors suppress senescent inflammation
CDK4/6 inhibitors reduce senescence-associated inflammation by disrupting a signaling pathway that links cell cycle control to NF-κB activation, improving physical function in aging and chemotherapy recovery. This identifies a mechanistic bridge between cellular aging and inflammatory dysfunction that may be pharmacologically addressable.
AMPK Activation Restores Metabolic Efficiency in Human Trial
Cambrian Bio's ATX-304 demonstrated in Phase 1b trials the ability to activate AMPK, a cellular energy regulator that declines with age. Participants showed improvements in liver fat, visceral adiposity, triglycerides, and resting metabolic rate without safety concerns—validating a mechanism long pursued in longevity research.
Senescent Microglia Drive Brain Aging—Reversible via Senotherapeutics
Senescent microglia accumulate in aging brains and drive neuroinflammation; targeted senotherapeutic interventions suppress this state and restore microglial function. This represents a mechanistic pathway to reduce age-related cognitive decline through cellular state modification rather than broad immunosuppression.
Akkermansia and postbiotics restore metabolic GLP-1 signaling
Designs for Health introduced Akkermansia Pro GLP-1 Probiotic, combining the keystone strain Akkermansia muciniphila with BPL1 postbiotic in an oxygen-protected delivery system. The formulation targets gut barrier integrity, endogenous GLP-1 production, and metabolic health through the microbiota–host axis.
Precision targeting of the SASP in cancer therapy
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts
Natural killer cells from older adults fail to clear senescent fibroblasts due to overactivation of the Cdc42 protein, which disrupts the cellular machinery required for releasing cytotoxic granules and producing ATP. Pharmacological inhibition of Cdc42 restores this clearing capacity and offers a potential therapeutic target for age-related disease driven by senescent cell accumulation.
Senescent Cell Distribution Across Tissues Enables Targeted Aging Intervention
Senescent cells accumulate across tissues with age and vary significantly by organ type and species, revealing tissue-specific patterns of cellular aging. This spatiotemporal map establishes a foundation for understanding which senescent populations drive age-related decline and represent therapeutic targets for longevity interventions.
Peptide Compounding Approval: What Regulated Access Actually Permits
An FDA advisory committee voted to recommend six peptides for inclusion on the Section 503A Bulks List, a decision that would permit regulated compounding but not blanket commercial access. The vote exposes a fundamental mismatch between regulatory frameworks designed for discrete disease treatment and the preventive interventions emerging in longevity medicine.
From “Passive Supplementation” to “Active Repair”: Melatonin Reshapes the Treatment Paradigm for Late‐Onset Hypogonadism by Targeting Leydig Cell Senescence
Melatonin restores testosterone production in aging Leydig cells by addressing oxidative stress and mitochondrial dysfunction, offering a mechanism-based alternative to passive testosterone supplementation. This shift from symptom management to cellular repair has implications for age-related hormonal decline in men.
Pulmatrix and Eos merge to advance gerotherapeutics
Pulmatrix and Eos SENOLYTIX are merging to develop PTC-2105, a candidate designed to modulate mitochondrial function and clear senescent cells in sarcopenia and metabolic disease. The transaction signals a fundamental shift in biopharma toward targeting aging biology directly rather than its downstream manifestations.
A Robust Senescence Response Helps Wounds Heal
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.
Gut microbes may influence GLP-1 drug response
Gut microbial composition significantly influences individual response to GLP-1 medications, with distinct bacterial patterns correlating to treatment efficacy and the ability of the microbiome to support metabolic signaling. This mechanism explains variable clinical outcomes and suggests microbiome profiling could predict responders before treatment initiation.
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
Advantages of Skeletal Muscle Preservation in Settings of Weight Loss
GLP-1 receptor agonists effectively reduce adiposity but simultaneously cause skeletal muscle loss, a consequence that diminishes metabolic efficiency and increases frailty risk in vulnerable populations. Preserving muscle mass during weight loss produces superior long-term metabolic outcomes and functional longevity compared to adiposity reduction alone.